Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 2026
28.4.2026 09:00:00 CEST | Business Wire | Press Release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in Barcelona. Roquette’s offering is designed to help consumer healthcare brands stay future‑ready and accelerate consumer-centric innovations for everyday well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428405433/en/
Credits to Roquette
As consumer expectations rise and shelf competition intensifies, dietary supplement and over-the-counter (OTC) brands, as well as contract development and manufacturing organizations (CDMOs), face growing pressure to deliver clean-label products that combine efficacy, strong sensory experiences, regulatory confidence, and speed to market. At Vitafoods Europe 2026, Roquette will demonstrate its role as a versatile partner, supporting customers from early concept to commercial launch across multiple dosage formats such as hard and softgel capsules, gummies, (mini) tablets, and chewables.
Where plant-based power meets high-end performance for diverse dietary requirements
“Roquette’s consumer healthcare business is built on a strong legacy of trusted and innovative ingredient brands,” said Laura Owens, Global Consumer Healthcare Marketing Leader for Roquette’s Health and Pharma Solutions Business Unit. “We are here to support supplement brands and CDMOs with solutions designed for today’s fastest growing consumer health needs such as GLP-1 related solutions, stress relief, or sustained sleep.”
Roquette’s broadened consumer healthcare portfolio and expertise has expanded after acquisitions to include Qualicaps hard capsules and former IFF Pharma Solutions brands such as SeaGel® carrageenan‑based softgel technology and VERDIGEL™ pectin premium for gummies. It offers everything needed to ensure supplement and OTC products are ready to meet diverse dietary requirements such as vegan, halal or kosher. Across formats, Roquette enables brands to deliver products that align with consumers’ well-being and health routines as well as clean-label expectations, ultimately building long-term value and trust.
What visitors will experience at the Roquette booth 3F112
In hall 3, booth 3F112, visitors will discover a broad range of formulation solutions designed for modern consumer healthcare applications including the following highlights:
- Capsules and Tablets: Precision Performance
Nutra’V hard HPMC capsules are designed for simplified and transparent formulations, with the entire range being titanium dioxide (TiO₂)-free to align with supplement market requirements and featuring a newly validated opacifying and whitening system
- Softgels: Next-Generation, Clean-Label Technologies
The nutraceutical softgel portfolio features SeaGel®, LYCAGEL® Flex hydroxypropyl pea starch-based softgel premix, and VERDIGEL™ SC pectin-starch premix, supporting plant-based and consumer-led softgel formulations that are ready to meet today’s regulatory and market expectations
- Gummies: Texture, Clarity, and Consistency
With solutions such as VERDIGEL™ Pectin Premium, Roquette will demonstrate how formulators can achieve premium bite, clarity, and reliable processability in clean-label and sugar-free gummy formats
- Taste and Mouthfeel: Sensory Experience as a Differentiator
Roquette will also highlight how PEARLITOL® SD mannitol and KLEPTOSE® encapsulation solutions can improve sweetness, mouthfeel, and taste masking — key factors for making supplements enjoyable and easy to take
To complete key aspects of the formulation cycle, visitors can also explore ReadiLYCOAT® film coating systems and HPMC/MCC nutraceutical and excipient systems designed for immediate or controlled release performance.
Why Roquette?
By partnering with Roquette, consumer healthcare brands and contract manufacturers benefit from:
- Multi-format formulation expertise across gummies, softgels, capsules, tablets, powders and suspensions
- Quality and regulatory assurance for consumer health applications
- Sustainable, plant-based solutions
- Technical partnership from ideation through commercialization
- Speed to market, supported by a CDMO‑friendly portfolio
Meet Roquette at Vitafoods Europe 2026:
May 5–7, at Fira Barcelona Gran Via, Barcelona, Spain
Hall 3, Booth 3F112
About Roquette
Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.
The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.
A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.
Together, we turn the potential of nature into the essentials of life.
Discover more about Roquette here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260428405433/en/
Contacts
Press Contact:
Roquette:
Lisa Luke
Global Head of Communications
Roquette’s Health & Pharma Solutions Business Unit
Email: lisa.luke@roquette.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press Release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Cinemo Honored with 2026 AutoX Award for Automotive Infotainment Innovation15.5.2026 08:05:00 CEST | Press Release
Cinemo, global leader in AI-powered, fully integrated in-vehicle entertainment and digital media solutions, delivering seamless multi-screen experiences for drivers and passengers, has been recognized as an Automotive Infotainment Innovator at the 2026 AutoX Innovator Awards by Compass Intelligence, highlighting its role in shaping the next generation of in-vehicle experiences. The AutoX Innovator Awards recognize companies that move the industry forward. Winners are selected based on criteria including technological advancement, differentiation, integration capabilities, user experience, industry partnerships, and feasibility. Additional emphasis is placed on real-world outcomes, such as improving driver safety, enhancing passenger experiences, delivering positive market impact, and transforming mobility. “Cinemo exemplifies the future of automotive infotainment, where innovation is defined not just by technology, but by the experiences it enables,” said Stephanie Atkinson, CEO of Com
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press Release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press Release
Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security that enterprises require. Through this collaboration, these signals can be serve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom